HST Global, Inc. (OTCPK: HSTC)
Health Care · Biotechnology · US
$0.65
— today · +6335.6% 1Y
HST Global, Inc. (OTCPK: HSTC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $91.93M and employs 1 people.
Over the last twelve months the share price has gained 6335.6%, trading between 0.01 and 1.05.
Tweenvest scores HST Global, Inc. across four factors: quality 27/100. Its strongest factor is quality.
HSTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $91.93M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -339.55
- 52-week high
- $1.05
- 52-week low
- $0.01
- Avg volume (3M)
- —
- Shares outstanding
- 141.43M
- Employees
- 1
- Next earnings
- —
About HST Global, Inc.
HST Global, Inc. operates as a biotechnology firm dedicated to integrated health and wellness. The company establishes and acquires a global network of specialized wellness centers, which offer homeopathic and alternative treatments primarily for patients suffering from advanced-stage cancers. Furthermore, HST Global focuses on the development of homeopathic and alternative therapeutic candidates that are either currently undergoing or have successfully completed clinical trials. These potential treatments are designed to address late-stage cancers as well as various other critical, life-threatening conditions. The company's corporate headquarters are situated in Hampton, Virginia.
- ISIN
- US40432E2028
- Listed since
- Jun 24, 2002
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.